Abstract | PURPOSE: MATERIALS AND METHODS: The PubMed/MEDLINE, EMBASE, Scopus, and ClinicalTrials.gov databases were searched with the term ' anakinra.' Results were manually screened to identify published data on off-label uses of anakinra in dermatologic conditions and systemic conditions with prominent dermatologic manifestations. RESULTS: CONCLUSION:
Anakinra is a potential option for patients with certain difficult-to-treat dermatologic diseases, given its relatively benign adverse effect profile and its effectiveness in a wide array of conditions. Overall, anakinra appears to be a promising option in the treatment of numerous dermatologic inflammatory conditions refractory to first line therapies, but further and higher-quality data is needed to clarify its therapeutic role.
|
Authors | Kyle Tegtmeyer, Giancarlo Atassi, Jeffrey Zhao, Nolan J Maloney, Peter A Lio |
Journal | The Journal of dermatological treatment
(J Dermatolog Treat)
Vol. 33
Issue 1
Pg. 73-86
(Feb 2022)
ISSN: 1471-1753 [Electronic] England |
PMID | 32279586
(Publication Type: Journal Article, Review)
|
Chemical References |
- Antirheumatic Agents
- Interleukin 1 Receptor Antagonist Protein
|
Topics |
- Antirheumatic Agents
(therapeutic use)
- Arthritis, Rheumatoid
(drug therapy)
- Dermatology
- Hidradenitis Suppurativa
(drug therapy)
- Humans
- Infant, Newborn
- Interleukin 1 Receptor Antagonist Protein
(therapeutic use)
- Off-Label Use
- Treatment Outcome
|